香港联交所最新资料显示，2月13日，GIC Private Limited增持大族数控（301200）(03200)9.34万股，每 股作价115.8746港元，总金额约为1082.27万港元。增持后最新持股数目约为858.19万股，最新持股比例 为17.01%。 ...

智通财经APP获悉，香港联交所最新资料显示，2月13日，GIC Private Limited增持大族数控(03200)9.34 万股，每股作价115.8746港元，总金额约为1082.27万港元。增持后最新持股数目约为858.19万股，最新 持股比例为17.01%。 ...

Core Viewpoint - GIC Private Limited has increased its stake in Adicon Holdings (09860), acquiring 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% ownership, triggering a mandatory disclosure [1] Group 1: Company Developments - Adicon's strategic focus on AI in medical testing has garnered significant market attention, transitioning from traditional models to intelligent and ecological approaches [1] - The company signed a cooperation agreement with Huawei Cloud in December, marking the beginning of a new chapter in smart healthcare powered by AI technology [1] - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million by November 2025, which will enhance its capabilities in drug development and diagnostics [1] Group 2: Market Reactions - Jefferies has issued a "Buy" rating for Adicon Holdings with a target price of HKD 12.60, citing the company's strategic moves in AI medical testing and the acquisition of Crown Bioscience as key factors [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical sector and solidifying its position as a leading quality asset in the industry [2]

Group 1 - GIC Private Limited increased its stake in Adicon Holdings (09860) by purchasing 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% of the company, officially triggering the takeover threshold [1] - Adicon's strategic focus on AI in medical testing has garnered significant market attention, as the company transitions its medical testing services from traditional models to intelligent and ecological approaches [1] - In December 2022, Adicon signed a cooperation agreement with Huawei Cloud to initiate a new chapter in smart healthcare powered by AI technology, showcasing its technological iteration path and forward-looking layout in AI medical innovation applications [1] Group 2 - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million, which is expected to significantly enhance the company's comprehensive strength in the drug development and diagnostic value chain [1] - Jefferies Financial has issued a "Buy" rating for Adicon Holdings (09860) with a target price of HKD 12.60, citing the company's strategic layout in AI medical testing and the acquisition of Crown Bioscience as major initiatives to strengthen its position [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical field and further solidifying its market position as a leading quality asset in the industry [2]

Group 1 - GIC Private Limited increased its stake in HAPO (02142.HK) by purchasing 500,000 shares at an average price of HKD 14.5128 per share, totaling approximately HKD 7.2564 million [1] - Following the purchase, GIC's total shareholding in HAPO rose to 71.954 million shares, increasing its ownership percentage from 7.99% to 8.05% [1]

Group 1 - GIC Private Limited increased its stake in Fuhong Hanlin (02696) by 38,300 shares at a price of HKD 67.5463 per share, totaling approximately HKD 2.587 million [1] - After the purchase, GIC's total shareholding in Fuhong Hanlin reached 11.4443 million shares, representing a 7% ownership stake [1]

Group 1 - GIC Private Limited increased its stake in Fuhong Hanlin (02696) by 38,300 shares at a price of HKD 67.5463 per share, totaling approximately HKD 2.587 million [1] - After the increase, GIC's total shareholding in Fuhong Hanlin reached 11.4443 million shares, representing a 7% ownership stake [1]

Group 1 - GIC Private Limited increased its stake in Fuhong Hanlin (02696) by acquiring 38,300 shares at a price of HKD 67.5463 per share, totaling approximately HKD 2.587 million [1] - After the acquisition, GIC's total shareholding in Fuhong Hanlin reached 11,444,300 shares, representing a 7% ownership stake [1]

Group 1 - GIC Private Limited increased its stake in Andlitz Pharmaceuticals (02142) by purchasing 500,000 shares at a price of HKD 14.5128 per share, totaling HKD 7.2564 million [1] - After the acquisition, GIC's total shareholding in Andlitz Pharmaceuticals reached 71.954 million shares, representing an ownership percentage of 8.05% [1]

Group 1 - GIC Private Limited increased its stake in Andlitz Pharmaceuticals (02142) by purchasing 500,000 shares at a price of HKD 14.5128 per share, totaling HKD 7.2564 million [1] - After the acquisition, GIC's total shareholding in Andlitz Pharmaceuticals reached 71.954 million shares, representing an ownership percentage of 8.05% [1]